Komori
Pharma Foods International (2929) · InitiativeAdvanced

Performance-Linked Restricted Stock Compensation System

First written in FY2021. 7 of 9 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2026.

9entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2022-Q1 – FY20262021: 220212022: 220222023: 120232024: 220242025: 120252026: 12026
Same theme, other companies
Performance-based executive and employee compensation schemeA theme 405 companies write about · 0 as a headwind · 397 as a tailwind

The whole theme swung hardest in 2024: 13 of 118 companies on the "Worse" side.

65 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 191 companies compared. The sentences above are computed from all 191.Comparing 200 of the theme's 418 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「The Company disposed of 228,576 treasury shares as restricted stock compensation.」

    For performance-linked restricted stock compensation, the Company disposed of 228,576 treasury shares with a total value of ¥169 million during the fiscal year.
  2. FY2025-H1AdvancedAnnual report

    「Based on a resolution of the Board of Directors meeting held on 22 October 2024, the company disposed of 872,400 treasury shares through a third-party allotment to ITOCHU Corporation. In addition, based on a resolution of the Board of Directors meeting held on 18 November 2024, the company disposed of 166,852 treasury shares as restricted stock compensation.」

    The company disposed of 872,400 treasury shares through a third-party allotment to ITOCHU Corporation and 166,852 shares as restricted stock compensation.
  3. FY2024RaisedAnnual report

    「At the 27th Annual General Meeting of Shareholders held on 24 October 2024, approval was obtained for total monetary compensation claims to be paid to directors other than outside directors as compensation and other consideration relating to restricted stock of no more than ¥200 million per year, and for a maximum total allocation of 200,000 restricted shares.」

    The company resolved to establish a new framework for restricted stock compensation, with an annual monetary limit of ¥200 million and a share limit of 200,000 shares.
  4. FY2024-Q2AdvancedAnnual report

    「Based on a resolution of the Board of Directors meeting held on 24 November 2023, the company disposed of 101,327 treasury shares as restricted stock compensation. As a result of this disposal, treasury shares decreased by ¥148 million during the cumulative second quarter of the current consolidated fiscal year.」

    For the restricted stock compensation approved on 24 November 2023, 101,327 treasury shares were disposed of and treasury shares decreased by ¥148 million.
  5. FY2024-Q1AdvancedAnnual report

    「At a meeting of the Board of Directors held on 24 November 2023, the company resolved to allocate 101,327 common shares as specified restricted stock. The allocation will be made through an in-kind contribution of all monetary compensation claims by the recipients, comprising total monetary compensation claims of ¥134 million paid to 6 eligible directors other than outside directors, 1 executive officer of the company and 10 directors of the company's subsidiary other than outside directors. The allocation covers restricted stock compensation for the eligible directors and the company's executive officer for the period from the company's 26th Annual General Meeting of Shareholders through the company's 29th Annual General Meeting of Shareholders scheduled for October 2026, and restricted stock compensation for the subsidiary directors for the period from the subsidiary's Annual General Meeting of Shareholders held in October 2023 through its Annual General Meeting of Shareholders scheduled for October 2026.」

    The company resolved to allocate 101,327 shares with a total value of ¥134 million to 17 directors, executive officers and subsidiary directors as restricted stock compensation. The covered period runs through the shareholders' meeting scheduled for October 2026.
  6. FY2023-Q1AdvancedAnnual report

    「At a meeting of the Board of Directors held on 18 November 2022, the company resolved to dispose of treasury shares as restricted stock compensation, as set out below. The payment procedures were completed on 6 December 2022.」

    Under the restricted stock compensation plan, 63,687 shares with a total value of ¥84 million were allocated to 12 directors and other officers, and payment was completed. This time, only Class II restricted shares linked to achievement of the medium-term management plan and other factors were allocated.
  7. FY2022AdvancedAnnual report

    「At the 24th Annual General Meeting of Shareholders held on 20 October 2021, approval was obtained for total monetary compensation claims to be paid to directors other than outside directors as compensation and other consideration relating to restricted stock of no more than ¥150 million per year, and for a maximum total allocation of 60,000 restricted shares.」

    Under the performance-linked stock compensation plan, the company recognized ¥26 million in performance-linked stock compensation for the fiscal year under a framework with an annual monetary limit of ¥150 million and an annual share limit of 60,000 shares.
  8. FY2022-Q1AdvancedAnnual report

    「At a meeting of the Board of Directors held on 15 November 2021, the company resolved to dispose of treasury shares as restricted stock compensation, as set out below (the "Treasury Share Disposal"). The payment procedures were completed on 2 December 2021.」

    Under the restricted stock compensation plan, 58,276 shares with a total value of ¥146 million were disposed of for 5 directors and 6 subsidiary directors, and payment was completed.
  9. FY2021First statedAnnual report

    「The number of restricted shares to be released will vary according to the achievement rate of the performance targets within a range of 80% to 120%. If the achievement rate is 120% or higher, all transfer restrictions will be released. If it is 80% or higher but below 120%, the transfer restrictions will be released in a proportion corresponding to the achievement rate. If it is below 80%, the transfer restrictions will not be released and all of the shares covered by this allocation will be acquired without compensation.」

    The company introduced a restricted stock compensation plan for directors other than outside directors, linked to the previous fiscal year's revenue and operating profit and the achievement of the medium-term management plan. The restriction period is 3 years or more, and the annual limit is 60,000 shares.
Moved together

"Research and Development Expenditure" moved the same way as this thread, in the same document, in 7 of its 9 moves.

776666★123456
  1. ★This thread
  2. 1Research and Development Expenditure7×
  3. 2Raising Working Capital through Borrowings7×
  4. 3Development of antibody therapeutics using proprietary chicken antibody technology6×
  5. 4Development of Medicated Hair Growth Product Nyumo as a New Core Product6×
  6. 5SDG Initiatives Through the Upcycling of Underutilized Resources6×
  7. 6Cost-effectiveness and profitability risks of advertising and promotional expenses6×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Performance-Linked Restricted Stock Compensation System | Pharma Foods International Co.,Ltd. (2929) | Komori